People: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

3,781.50GBp
17 Apr 2014
Price Change (% chg)

23.00p (+0.61%)
Prev Close
3,758.50p
Open
3,775.00p
Day's High
3,795.00p
Day's Low
3,757.00p
Volume
1,844,021
Avg. Vol
2,562,642
52-wk High
4,138.33p
52-wk Low
3,028.50p

Search Stocks

Summary

Name Age Since Current Position

Leif Johansson

63 2012 Non-Executive Independent Chairman of the Board

Pascal Soriot

54 2012 Chief Executive Officer, Executive Director

Marc Dunoyer

2013 Chief Financial Officer, Executive Director

Lynn Tetrault

2007 Executive Vice President - Human Resources and Corporate Affairs

Ruud Dobber

2013 Executive Vice President, Europe

Paul Hudson

2013 Executive Vice President, North America

Bahija Jallal

2013 Executive Vice President, MedImmune

Mark Mallon

2013 Executive Vice President, International

Briggs Morrison

2013 Executive Vice President - Global Medicines Development

Menelas Pangalos

2013 Executive Vice President - Innovative Medicines

David Smith

2010 Executive Vice President - Operations and Information Services

Katarina Ageborg

2011 Chief Compliance Officer

Jeffrey Pott

2009 General Counsel

Adrian Kemp

2009 Company Secretary

John Varley

57 2012 Senior Independent Non-Executive Director

Genevieve Berger

59 2012 Non-Executive Director

Marcus Wallenberg

58 1999 Non-Executive Director

Bruce Burlington

64 2010 Non-Executive Independent Director

Graham Chipchase

50 2012 Non-Executive Independent Director

Jean-Philippe Courtois

52 2008 Non-Executive Independent Director

Rudolph Markham

68 2008 Non-Executive Independent Director

Nancy Rothwell

57 2006 Non-Executive Independent Director

Shriti Vadera

51 2011 Non-Executive Independent Director

James Ward-Lilley

IR Contact Officer

Biographies

Name Description

Leif Johansson

Mr. Leif Johansson has been appointed as Non-Executive Independent Chairman of the Board of AstraZeneca Plc. Elected as a Director in April 26, 2012 and became Non-Executive Chairman of the Board on June 1, 2012. Leif Johansson is also the Chairman of global telecommunications company, LM Ericsson, a position he has held since April 2011. From 1997 until 2011, he was Chief Executive of AB Volvo, one of the world’s manufacturers of trucks, buses, construction equipment, drive systems and aerospace components. He spent a part of his early career at AB Electrolux, latterly as Chief Executive from 1994 to 1997. He was a Non-Executive Director of BMS from 1998 to September 2011, serving on the board’s audit committee and compensation and management development committee. He is Chairman of the European Round Table of Industrialists and the International Advisory Board of the Nobel Foundation. He holds board positions at Svenska Cellulosa Aktiebolaget SCA and Ecolean AB. He holds an MSc in engineering from Chalmers University of Technology, Gothenburg, and has been a member of the Royal Swedish Academy of Engineering Sciences since 1994. He became Chairman of the Academy in 2012.

Pascal Soriot

Mr. Pascal Soriot has been appointed Chief Executive Officer and Executive Director at AstraZeneca PLC., effective from October 1, 2012. From 2010 to September 2012, he served as Chief Operating Officer of Roche AG’s pharmaceuticals division. Prior to that, he was CEO of Genentech, a biologics business, and led its merger with Roche. He joined the pharmaceutical industry in 1986 and has worked in senior management roles throughout the world in a number of companies since then. He brings to AstraZeneca a breadth of experience in both established and emerging markets, strength of strategic thinking, a track record of managing change and putting strategy into operation, as well as the ability to lead a diverse organisation having lived in Australia, Japan, the US and Europe. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from L’Institut Supérieur des Affaires, Jouy-en-Josas.

Marc Dunoyer

Mr. Marc Dunoyer has been appointed as Chief Financial Officer, Executive Director of AstraZeneca PLC, effective 1 November 2013. He joined AstraZeneca from GlaxoSmithKline in June 2013. Marc qualified as an accountant. His subsequent career in pharmaceuticals has given him extensive experience of the industry including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development. A French national with a background in finance and accounting, Marc Dunoyer began his career in the pharmaceutical industry at Roussel Uclaf in Paris in the 1970s before being promoted to the position of President, Japan and then President, Asia Pacific. After returning to France for a period as Managing Director, Global Pharmaceuticals Division, Roussel Uclaf in the 1990s, Marc was appointed President & CEO, Asia Pacific & Japan for Hoechst Marion Roussel in 1995. In 2000, he was recruited by Glaxo Wellcome - just ahead of the merger that created GlaxoSmithKline - as Regional President, Japan and subsequently Regional President, Asia Pacific & Japan. His most recent role before joining AstraZeneca was Global Head of Rare Diseases and (concurrently) Chairman, GSK Japan for GlaxoSmithKline. Marc has an MBA from the Hautes Etudes Commerciales and has a Bachelor of Law degree from Paris University. He qualified as a Junior Certified Public Accountant in France.

Lynn Tetrault

Ms. Lynn Tetrault is Executive Vice President - Human Resources and Corporate Affairs of AstraZeneca PLC. Lynn was appointed Executive Vice-President, Human Resources and Corporate Affairs in 2007, having previously been Vice-President, Corporate Affairs. She has also held the role of Vice-President HR, Global Drug Development and Vice-President, HR for the US subsidiary of AstraZeneca following the merger between Astra and Zeneca. She started her career in private law practice where she specialised in general corporate and healthcare law. She joined Astra USA in 1993 as Associate General Counsel in the company’s legal department. She received her bachelor’s degree from Princeton University and her law degree from the University of Virginia Law School.

Ruud Dobber

Mr. Ruud Dobber is the Executive Vice President, Europe of AstraZeneca PLC., since January 2013 and leads AstraZeneca’s commercial operations in Europe. In this capacity, Ruud is responsible for sales, marketing and commercial operations across AstraZeneca’s businesses in the 27 EU member states. Ruud joined AstraZeneca in 1997 and has held a number of senior commercial roles including Regional Vice- President of AstraZeneca’s European, Middle East and African division and Regional Vice- President for the Group’s Asia Pacific region. Since 2012, Ruud has been an Executive Committee Member of EFPIA. In 2011, Ruud was the Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America. Ruud commenced his career as a scientist, researching in the field of immunology and ageing. He holds a doctorate in immunology from the University of Leiden in the Netherlands.

Paul Hudson

Mr. Paul Hudson is the Executive Vice President, North America of AstraZeneca PLC., since January 2013 and leads AstraZeneca’s commercial operations in North America. In this capacity, he is accountable for driving growth and maximising the contribution of North America to AstraZeneca’s global business. Paul joined AstraZeneca in 2006 as Vice-President and Primary Care Director, UK. Paul’s most recent role with AstraZeneca was President of AstraZeneca’s Japanese business. He has served as a Standing Board Member of Japan Pharmaceuticals Manufacturers Association and EFPIA in Japan. Previously, Paul was President of AstraZeneca’s business in Spain. Before AstraZeneca, Paul worked for Schering-Plough, where he held senior global marketing roles. Paul received a degree in economics from Manchester Metropolitan University and a DipM from the UK’s Chartered Institute of Marketing.

Bahija Jallal

Dr. Bahija Jallal is the Executive Vice President, MedImmune of AstraZeneca PLC., since January 2013 and is responsible for biologics research, development and clinical activities. Bahija is tasked with advancing the biologic pipeline of drugs. Bahija joined MedImmune as Vice-President, Translational Sciences in 2006 and has held roles of increasing responsibility. Prior to joining AstraZeneca, Bahija worked with Chiron Corporation where she served as Vice-President, Drug Assessment and Development. Bahija received a master’s degree in biology from the Université de Paris VII and her doctorate in physiology from the Université Pierre et Marie Curie, Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany. She is a member of the American Association of Cancer Research, the American Association of Science, the Pharmacogenomics Working Group and is a member of the Board of Directors of the Association of Women in Science.

Mark Mallon

Mr. Mark Mallon is the Executive Vice President, International of AstraZeneca PLC., since January 2013 and is responsible for the growth and performance of AstraZeneca’s commercial businesses in regions including Asia Pacific, Russia, Latin America, the Middle East and Africa. Since joining AstraZeneca in 1994, Mark has held a number of senior sales and marketing roles including Regional Vice-President for Asia Pacific, President of AstraZeneca China and head of marketing, sales and commercial operations for AstraZeneca in Japan. Mark has a degree in chemical engineering from the University of Pennsylvania and an MBA in marketing and finance from the Wharton School of Business.

Briggs Morrison

Dr. Briggs Morrison is the Executive Vice President - Global Medicines Development of AstraZeneca PLC., since January 2013 and leads the global late-stage development organisation for both small molecules and biologics. He joined AstraZeneca in 2012 from Pfizer, where he was Head of Medical Excellence, overseeing development, medical affairs, safety and regulatory affairs for Pfizer’s human health businesses. Briggs has a track record of developing novel medicines in roles at both Pfizer and Merck. Briggs has a biology degree from Georgetown University and a medical doctorate from the University of Connecticut. Briggs has also undertaken an internship and residency in internal medicine at the Massachusetts General Hospital, a fellowship in medical oncology at the Dana-Farber Cancer Institute and a post-doctoral research fellowship in genetics at Harvard Medical School.

Menelas Pangalos

Mr. Menelas Pangalos is the Executive Vice President - Innovative Medicines of AstraZeneca PLC., since January 2013 and leads AstraZeneca’s small molecule discovery research and early development activities. Mene joined AstraZeneca from Pfizer, where he was Senior Vice-President and Chief Scientific Officer of Neuroscience Research. Previously, Mene held senior discovery and neuroscience roles at Wyeth and GSK. He completed his undergraduate degree in biochemistry at the Imperial College of Science and Technology, London and earned a doctorate in neurochemistry from the University of London. He is a Visiting Professor of Neuroscience at King’s College, London. In the UK, Mene sits on the Medical Research Council and the Innovation Board for the Association of the British Pharmaceutical Industry.

David Smith

Mr. David Smith is Executive Vice President - Operations and Information Services of AstraZeneca Plc. David joined AstraZeneca in 2006 as Executive Vice-President, Operations. He leads AstraZeneca’s global manufacturing and supply organisation and is also responsible for the Safety, Health and Environment, Regulatory Compliance, Procurement and Engineering functions and has overall responsibility for IS. He spent his early career in pharmaceuticals, initially with the Wellcome Foundation in the UK. He subsequently spent nine years in the consumer goods sector working for Estée Lauder Inc. and Timberland LLC in senior supply chain roles. In 2003, he returned to the pharmaceutical sector and joined Novartis in Switzerland.

Katarina Ageborg

Ms. Katarina Ageborg is Chief Compliance Officer of AstraZeneca PLC. Katarina was appointed Chief Compliance Officer in July and has overall responsibility for the delivery, design and implementation of AstraZeneca’s compliance responsibilities. Since joining AstraZeneca in 1998, she has held a series of senior legal roles supporting Commercial and Regulatory and most recently led the Global IP function from 2008 to 2011. Prior to joining AstraZeneca, she established her own law firm in Sweden and worked as a lawyer practising on both civil and criminal cases.

Jeffrey Pott

Mr. Jeffrey Pott is General Counsel of AstraZeneca Plc. Jeff was appointed General Counsel in January 2009 and has overall responsibility for all aspects of AstraZeneca’s Legal and IP function. He joined AstraZeneca in 1995 and has worked in various litigation roles, where he has had responsibility for IP, anti-trust and product liability litigation. Prior to joining AstraZeneca, he spent five years at the US legal firm Drinker Biddle and Reath LLP, where he specialised in pharmaceutical product liability litigation and anti-trust advice and litigation. He received his bachelor’s degree in political science from Wheaton College and his Juris Doctor Degree from Villanova University School of Law.

Adrian Kemp

John Varley

Mr. John Silvester Varley has been appointed as Senior Independent Non-Executive Director of AstraZeneca PLC, effective April 26, 2012. Appointed as a Director in July 2006. John was formerly Group Chief Executive of the Barclays Group, having held a number of senior positions with the bank during his career, including that of Group Finance Director. He brings additional international, executive business leadership experience to the Board. He is also a Non-Executive Director of BlackRock, Inc., and Rio Tinto plc and Rio Tinto Limited, Chairman of Business Action on Homelessness and of Marie Curie Cancer Care, President of the Employers’ Forum on Disability, a member of the International Advisory Panel of the Monetary Authority of Singapore and Honorary President of the UK Drug Policy Commission.

Genevieve Berger

Professor Genevieve Berger has been appointed as Non-Executive Director of AstraZeneca Plc., effective April 26, 2012. Geneviève Berger is Chief Science Officer at Unilever PLC and a member of the Unilever Leadership Executive. She holds three doctorates – in physics, human biology and a medical doctorate. She was appointed Professor of Medicine at Université Pierre et Marie Curie, Paris in 2006. From 2003 to 2008 she was Professor and Hospital Practitioner at l’Hôpital de la Pitié-Salpêtrière, Paris. Previous positions she has held include Director of the Biotech and Agri-Food Department, then Head of the Technology Directorate at the French Ministry of Research and Technology (1998-2000); Director General, Centre National de la Recherche Scientifique (2000-2003); and Chairman of the Health Advisory Board of the EU Commission (2006-2008). She was a non-executive board member of Unilever from 2007 to 2008 before being appointed to her current position and was a Non-Executive Director of Smith & Nephew plc from 2010 to 2012.

Marcus Wallenberg

Mr. Marcus Wallenberg is Non-Executive Director of AstraZeneca PLC. Appointed as a Director in April 1999. Marcus has international business experience across a broad range of industry sectors, including the pharmaceutical industry from his directorship with Astra AB prior to 1999. He is the Chairman of Skandinaviska Enskilda Banken AB, AB Electrolux, Saab AB and LKAB, and a Non-Executive Director of Stora Enso Oyj, Temasek Holdings Limited and the Knut and Alice Wallenberg Foundation.

Bruce Burlington

Dr. Bruce Burlington is Non-Executive Independent Director of AstraZeneca Plc. Bruce is a pharmaceutical product development and regulatory affairs consultant and brings experience in those areas to the Board. He is also a non-executive board member of Cangene Corporation and a member of the scientific advisory boards of the International Medical Foundation and H. Lundbeck A/S. Previously he spent 17 years with the FDA, serving as director of the FDA’s Center for Devices and Radiological Health as well as holding a number of senior roles in the Center for Drug Evaluation and Research. After leaving the FDA he served in a series of senior executive positions at Wyeth (now part of Pfizer).

Graham Chipchase

Mr. Graham Chipchase has been appointed as Non-Executive Independent Director of AstraZeneca PLC., effective April 26, 2012. Graham Chipchase is the Chief Executive of global consumer packaging company, Rexam PLC. He was appointed to the position in 2010 after previous service at Rexam as Group Director, Plastic Packaging (2005-2009) and Group Finance Director (2003-2005). Prior to joining Rexam, he was Finance Director of Aerospace Services at global engineering group, GKN plc, from 2001 to 2003. After starting his career with Coopers & Lybrand Deloitte, he held a number of finance roles in the industrial gases company, The BOC Group plc (now part of The Linde Group) (1990-2001). He is a Fellow of the Institute of Chartered Accountants in England and Wales and holds an MA (Hons) in chemistry from Oriel College, Oxford.

Jean-Philippe Courtois

Mr. Jean-Philippe Courtois is Non-Executive Independent Director of AstraZeneca Plc. Appointed as a Director in February 2008. Jean-Philippe has close to 30 years’ experience in the global technology industry and is President of Microsoft International, a board member of PlaNet Finance and Microsoft’s official representative at the Institut Montaigne. Previously he was Chief Executive Officer and President of Microsoft EMEA and has served as co-chairman of the World Economic Forum’s Global Digital Divide Initiative Task Force and on the European Commission Information and Communication Technology Task Force. In 2009, he also served as an EU Ambassador for the Year of Creativity and Innovation and in 2011 was named as one of ‘Tech’s Top 25’ by The Wall Street Journal Europe.

Rudolph Markham

Mr. Rudy H. P. Markham is Non-Executive Independent Director of AstraZeneca Plc since September 12, 2008. Rudy Markham takes a particular interest on behalf of the Board in SHE assurance. He has international business and financial experience, having formerly held a number of senior commercial and financial positions worldwide with Unilever, culminating in his appointment as Chief Financial Officer of Unilever. He is currently Chairman and Non- Executive Director of Moorfields Eye Hospital NHS Foundation Trust and a non-executive member of the boards of United Parcel Services Inc., Standard Chartered PLC and Legal & General plc. He is also a non-executive member of the board of the UK Foreign and Commonwealth Office, a member of the supervisory board of CSM NV, a Fellow of the Chartered Institute of Management Accountants and a Fellow of the Association of Corporate Treasurers. He served as a Non-Executive Director of the UK Financial Reporting Council from 2007 to 2012.

Nancy Rothwell

Professor Dame Nancy Rothwell is Non-Executive Independent Director of AstraZeneca PLC, since April 27, 2006. Nancy Rothwell oversees responsible business on behalf of the Board, as is described more fully in the Responsible Business section from page 48. She is a distinguished life scientist and academic and is the President and Vice-Chancellor of the University of Manchester. She is also President of the Society of Biology and Co-Chair of the Prime Minister’s Council for Science and Technology. Previously she has served as President of the British Neuroscience Association and has been on the councils of the Medical Research Council, the Royal Society, the Biotechnology and Biological Sciences Research Council, the Academy of Medical Sciences and Cancer Research UK.

Shriti Vadera

The Right Honourable Baroness Shriti Vadera is Non-Executive Independent Director of AstraZeneca PLC., since January 1, 2011. Shriti has experience of emerging markets, and knowledge of global finance and public policy. She is a Non-Executive Director of BHP Billiton Plc and BHP Billiton Limited. She advises funds, governments and companies and has recently undertaken a number of international assignments including advising the Republic of Korea as Chair of the G20, the government of Dubai on the restructuring of Dubai World, Temasek Holdings, Singapore on strategy and Allied Irish Banks on restructuring and European policy. She was Minister in the UK government from 2007 to 2009, most latterly in the Cabinet Office and Business Department, working on the government’s response to the financial crisis. From 1999 to 2007, she was on the Council of Economic Advisers, HM Treasury focusing on business and international economic issues. Prior to that she spent 14 years in investment banking with S G Warburg/ UBS in banking, project finance and corporate finance specialising in emerging markets.

James Ward-Lilley

Search Stocks